Report Company Directory
- William Blair Healthcare Research Team: Quarterly Post-Earnings Wrap-Up Call – Supplemental Deck by William Blair
- Agrees to Be Acquired by UCB for $26.00 With a $2.00 CVR Offering; Downgrading to Market Perform by William Blair
- Omicron Drives New Infections to Dizzying Heights and New Hospitalization Peaks; Early Signals Point to Potential Inflection by William Blair
- Key JPM 2022 Themes and Takeaways Chat With the William Blair Biotech Team: Friday, January 21, at 12.00 p.m. ET by William Blair
- William Blair Healthcare Research Team: Quarterly Post-Earnings Wrap-Up Call – Friday, May 20, at 11 a.m. ET by William Blair
- Dropping Coverage Following Acquisition by UCB by William Blair
- ZGNX | Dropping Coverage Post Acquisition By UCB by Raymond James
- Fast Forward No. 589 by William Blair
- Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022 by GlobeNewsWire
- Raymond James Morning Notes - BBY, BRP, FANG, IAS, PSN, REGI, TGLS, WHF, XPOF, ZION by Raymond James